The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for FHC sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
FHC is a medical device company that manufactures, designs, and distributes products for neurology market. The company’s products include positioning, stereotaxy, recording and stimulating, microelectrodes and insertion tubes, navigation system and neuroscience research. Its clinical microtargeting products include clinical electrodes, clinical insertion tubes, clinical devices, clinical platform and clinical systems. FHC also designs and manufactures microelectrodes, microdrives, surgery planning software, patient customized devices, neuromodulation systems, and neuroscience research equipment. The company provides research equipment such as research electrodes, research devices, and research systems. Its services include clinical services, clinical tech support and product maintenance. The company has its operations in the US, Romania and Colombia. FHC is headquartered in Bowdoin, Maine, the US. Key subsidiaries of FHC include Atanse.
The key metrics of FHC related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As FHC is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as FHC.
For a detailed understanding of the performance of FHC, buy the report here.